News

In the study, patients receiving oral Xeloda plus oxaliplatin (Xelox) lived for a median of 19 months, while patients receiving Folfox-4 lived for a median of 18.5 months.

Under the terms of the agreement, Abbott will commence a tender offer by January 26, 2009, to purchase all outstanding shares of Advanced Medical Optics (AMO) at $22

This 24-patient two-cohort, five-arm crossover study included administration of open-label oral triazolam and IV sufentanil on days one and two followed by a double-blinded, randomized dosing of a

Anthera’s fewer recurrent acute coronary events with near-term cardiovascular inflammation suppression (Francis) trial is based upon direct feedback from the FDA via the special protocol assessment procedure. The

The company intends to file a motion with the Bankruptcy Court to implement bid procedures for the sale of the company or its assets, following which potential bidders

The study was conducted in normal healthy volunteers with serum uric acid above 5mg/dl. The results of this study demonstrated that single doses of up to 600mg of

The Independent Safety Monitoring Board’s (ISMB) decision is based on safety assessments of the first five patients to complete at least 30 days of follow up following treatment

In a three-year research collaboration, Biotica will use its bioengineering technology to produce compounds that are not readily accessible via conventional medicinal chemistry approaches. GlaxoSmithKline (GSK) will apply

In his role as vice president of research and development, Ling manages IBT’s development of new tests in allergy and immunology. He brings with him over 25 years